Drug Profile
Cerdulatinib - Dermavant Sciences/Alexion AstraZeneca Rare Disease
Alternative Names: ALXN 2075; DMVT 502; Dual-SYK/JAK-inhibitor-Alexion AstraZeneca Rare Disease; PRT-062070; PRT-2070; RVT-502; RVT-502 - Dermavant SciencesLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Portola Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Dermavant Sciences; NicOx; Portola Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Cyclopropanes; Eye disorder therapies; Piperazines; Pyrimidines; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
- Discontinued Allergic rhinitis; Atopic dermatitis; Eye disorders; Vitiligo
Most Recent Events
- 19 Mar 2024 Alexion Pharmaceuticals completes a expanded access programme in Chronic lymphocytic leukemia and Non-hodgkin's lymphoma in March 2024 (NCT04757259)
- 28 Jun 2022 Discontinued (due to company-wide cost optimization and pipeline reprioritization) - Phase-I for Vitiligo in United Kingdom (Topical)
- 28 Jun 2022 Discontinued - Phase-I for Atopic dermatitis in United Kingdom (Topical)